RELAX-AHF-II
A multicenter, randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety and tolerability of Serelaxin when added to standard therapy in acute heart failure patients
- Stage
- klaar
- Medicine
- RLX030 serelaxine
- Population
- Hartfalen
- Phase
- III
- First Patient In
- 15 November 2013
- Last Patient In
- 26 July 2016
- Last Patient Last Visit
- -
Study Director
